Key facts
- It has raised $75.3M across 2 recorded rounds; the latest was Early Stage VC ($16.8M) in Sep 2025.
- Notable investors include Gates Foundation, Cockrell Interests, Sandia Holdings, Tanis Venture Management, Ziff Capital Partners.
- Corner Therapeutics has filed 3 Form Ds with the SEC since 2024, most recently Aug 2025 ($58.5M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Corner Therapeutics
Funding rounds
2 roundsAbout Corner Therapeutics
Provider of biotechnology research services intended to stimulate exceptional memory T cells for lifelong immunity. The company's technologies offer a versatile dendritic cell hyperactivation (hDC) platform that induces exceptional T-cell responses, providing robust and durable immunity against a virtually unbounded range of cancers and infectious diseases, enabling healthcare providers to promote durable immunity and ensure the apex of immune regulators.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2020
- Employees
- 35
- Website
- cornertx.com/
- Ownership
- Privately Held (backing)
Corner Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Corner Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Corner Therapeutics in its N-PORT filings yet. We sweep new filings monthly.